Good Manufacturing Practices Production of Mesenchymal Stem/Stromal Cells
- 28 October 2010
- journal article
- review article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 22 (1) , 19-26
Abstract
Because of their multi/pluripotency and immunosuppressive properties mesenchymal stem/stromal cells (MSCs) are important tools for treating immune disorders and for tissue repair. The increasing use of MSCs has led to production processes that need to be in accordance with Good Manufacturing Practice (GMP). In cellular therapy, safety remains one of the main concerns and refers to donor validation, choice of starting material, processes, and the controls used, not only at the batch release level but also during the development of processes. The culture processes should be reproducible, robust, and efficient. Moreover, they should be adapted to closed systems that are easy to use. Implementing controls during the manufacturing of clinical-grade MSCs is essential. The controls should ensure microbiological safety but also avoid potential side effects linked to genomic instability driving transformation and senescence or decrease of cell functions (immunoregulation, differentiation potential). In this rapidly evolving field, a new approach to controls is needed.Keywords
This publication has 53 references indexed in Scilit:
- Mutations in Bone Marrow-Derived Stromal Stem Cells Unmask Latent MalignancyStem Cells and Development, 2010
- Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory propertiesProceedings of the National Academy of Sciences, 2010
- A novel serum-free medium for the expansion of human mesenchymal stem cellsStem Cell Research & Therapy, 2010
- A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human OrgansCell Stem Cell, 2008
- Effect of Platelet-rich Plasma on the in vitro Proliferation and Osteogenic Differentiation of Human Mesenchymal Stem Cells on Distinct Calcium Phosphate Scaffolds: The Specific Surface Area Makes a DifferenceJournal of Biomaterials Applications, 2008
- Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapiesMechanisms of Ageing and Development, 2008
- Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose TissueStem Cells, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Study of Telomere Length Reveals Rapid Aging of Human Marrow Stromal Cells following In Vitro ExpansionStem Cells, 2004
- Adult human mesenchymal stem cell as a target for neoplastic transformationOncogene, 2004